Your session is about to expire
← Back to Search
Anti-metabolites
Nab-paclitaxel for Pancreatic Cancer
Phase 2
Recruiting
Led By Laith Abushahin, MBBS
Research Sponsored by Laith Abushahin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patient has one or more metastatic tumors measurable by computed tomography (CT) scan (or magnetic resonance imaging [MRI], if patient is allergic to CT contrast media or if the tumor is difficult to delineate on CT scan) as defined by RECIST 1.1 criteria
Participant has definitive histologically or cytologically confirmed adenocarcinoma of the pancreas. The definitive diagnosis of metastatic pancreatic adenocarcinoma will be made by integrating the histopathological data within the context of the clinical and radiographic data. Participants with islet cell neoplasms are excluded
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
Study Summary
This trial is studying a new way of giving gemcitabine and nab-paclitaxel to see if it works better than the standard way in treating pancreatic cancer.
Who is the study for?
This trial is for adults with metastatic pancreatic adenocarcinoma confirmed by tissue analysis. Participants must have measurable tumors, not be pregnant or breastfeeding, and agree to use effective contraception. No prior chemotherapy for metastatic cancer is allowed, but past adjuvant therapy over 6 months ago is acceptable. They need a certain level of blood cells (neutrophils, platelets) and hemoglobin.Check my eligibility
What is being tested?
The study tests an optimized infusion schedule of two chemotherapy drugs: Gemcitabine and Nab-paclitaxel in patients with advanced pancreatic cancer. The goal is to see if changing the timing of Nab-paclitaxel improves treatment outcomes.See study design
What are the potential side effects?
Potential side effects include nausea, fatigue, hair loss, low blood cell counts leading to increased infection risk or bleeding problems, nerve damage causing numbness or pain in hands and feet (neuropathy), and allergic reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have at least one tumor that can be measured on a CT or MRI scan.
Select...
I have been diagnosed with a specific type of pancreatic cancer, not islet cell cancer.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Heart rate
Secondary outcome measures
Disease control rate
Incidence of adverse events (AEs)
Overall survival (OS)
+2 moreSide effects data
From 2016 Phase 3 trial • 50 Patients • NCT0201927770%
Diarrhoea
68%
Fatigue
56%
Neuropathy peripheral
54%
Alopecia
52%
Rash
46%
Nausea
38%
Upper respiratory tract infection
36%
Myalgia
34%
Vomiting
34%
Headache
28%
Muscle spasms
24%
Nail disorder
24%
Gastrooesophageal reflux disease
24%
Epistaxis
24%
Arthralgia
22%
Pain in extremity
20%
Back pain
20%
Urinary tract infection
18%
Dizziness
18%
Cough
18%
Constipation
16%
Neutropenia
16%
Dry skin
14%
Pyrexia
14%
Paronychia
14%
Dysgeusia
14%
Oropharyngeal pain
14%
Pruritus
14%
Hot flush
12%
Hypertension
12%
Dry eye
12%
Stomatitis
12%
Decreased appetite
12%
Musculoskeletal pain
12%
Insomnia
12%
Dyspnoea
10%
Peripheral sensory neuropathy
10%
Abdominal pain
10%
Mucosal inflammation
10%
Lethargy
8%
Febrile neutropenia
8%
Rash pustular
8%
Lacrimation increased
8%
Chills
8%
Anaemia
8%
Oedema peripheral
8%
Oral candidiasis
8%
Sinusitis
8%
Anxiety
8%
Rhinorrhoea
8%
Acne
8%
Erythema
6%
Musculoskeletal chest pain
6%
Injection site reaction
6%
Skin lesion
6%
Conjunctivitis
6%
Nail infection
6%
Chest pain
6%
Tachycardia
6%
Abdominal pain upper
6%
Dry mouth
6%
Dyspepsia
6%
Chest discomfort
6%
Pain
6%
Hypocalcaemia
6%
Bone pain
6%
Depression
6%
Dyspnoea exertional
6%
Dermatitis acneiform
6%
Lymphoedema
6%
Weight decreased
6%
Tooth extraction
4%
Pulmonary embolism
4%
Cellulitis
2%
Psychotic disorder
2%
Syncope
2%
Dermatitis bullous
2%
Gastroenteritis
2%
Femur fracture
2%
Breast cancer
2%
Device related infection
2%
Wound infection
2%
Cardiac failure
2%
Drug hypersensitivity
2%
Gastritis
2%
Dermatomyositis
2%
Oesophagitis
2%
Sepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Trastuzumab, Pertuzumab, and Taxane
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (gemcitabine, nab-paclitaxel)Experimental Treatment2 Interventions
Patients receive gemcitabine IV over 30 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Albumin human
FDA approved
Gemcitabine
FDA approved
Find a Location
Who is running the clinical trial?
Laith AbushahinLead Sponsor
National Cancer Institute (NCI)NIH
13,667 Previous Clinical Trials
40,926,079 Total Patients Enrolled
Anne NoonanLead Sponsor
1 Previous Clinical Trials
9 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any available slots for patients to participate in this research study?
"Indeed, as per clinicaltrials.gov, this ongoing clinical trial is currently seeking eligible candidates. The initial posting of the trial was on June 24th, 2020, and it has been periodically updated with the most recent update made on December 27th, 2023."
Answered by AI
What is the upper limit on the number of patients who can participate in this medical study?
"Indeed, the information obtained from clinicaltrials.gov indicates that this trial is currently in need of participants. The initial posting of the trial took place on June 24th, 2020 and it was last modified on December 27th, 2023. In order to complete the study successfully, a total of 53 individuals are required across one designated site."
Answered by AI
Has the Food and Drug Administration (FDA) given its official endorsement to Nab-paclitaxel?
"Given the nature of this Phase 2 trial, our team at Power rates the safety of Nab-paclitaxel as a 2. While there is some existing data supporting its safety profile, there is currently no evidence regarding its efficacy for the intended purpose."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger